Treatment with growth hormone receptor antagonist in acromegaly: Effect on cardiac structure and performance

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 2, 2007, Pages 476-482

  Pivonello, Rosario ^a   Galderisi, Maurizio ^a   Auriemma, Renata S ^a   De Martino, Maria Cristina ^a   Galdiero, Mariano ^a   Ciccarelli, Antonio ^a   D'Errico, Arcangelo ^a   Kourides, Ione ^b   Burman, Pia ^b   Lombardi, Gaetano ^a   Colao, Annamaria ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GROWTH HORMONE DERIVATIVE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN BINDING PROTEIN 1;

ACROMEGALY; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR PERFORMANCE; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOPPLER ECHOCARDIOGRAPHY; DOSE CALCULATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HEART EJECTION FRACTION; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE PERFORMANCE; HEART MUSCLE RELAXATION; HEART VENTRICLE FUNCTION; HORMONE DETERMINATION; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LOADING DRUG DOSE; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY; SIDE EFFECT; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 33846964162     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-1587     Document Type: Article

References (28)

1. Colao A, Ferone D, Marzullo P, Lombardi G 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:105-152
2. Clayton RN 2003 Cardiovascular function in acromegaly. Endocr Rev 24:272-274
3. Melmed S 1990 Acromegaly. N Engl J Med 322:966-977
4. Colao A, Pivonello R, Cappabianca P, Vitale G, Lombardi G 2003 The treatment algorithm of acromegaly. J Endocrinol Invest 26(Suppl 8):39-45
5. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ 2002 Growth hormone receptor antagonist: discovery, development and use in patients with acromegaly. Endocr Rev 23:623-646
6. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO 2001 Long term treatment of acromegaly with pegvisomant, a growth hormone antagonist. Lancet 358:1754-1759
7. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G 2006 Efficacy of 12-months of treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
8. Galderisi M, Petrocelli A, Alfieri A, Garofalo M, de Divitiis O 1996 Impact of ambulatory blood pressure on left ventricular diastolic dysfunction in uncomplicared arterial hypertension. Am J Cardiol 77:597-601
9. Devereux RB, Reichek N 1977 Echocardiographic determination of left ventricular mass: anatomic validation of the method. Circulation 55:613-618
10. Colao A, Marzullo P, Di Somma C, Lombardi G 2001 Growth hormone and the heart. Clin Endocrinol 54:137-154
11. Isgaard J, Tivesten A, Friberg P, Bengtsson B-A 1999 The role of the GH/IGF-I axis for the cardiac function and structure. Horm Metab Res 31:50-54
12. Isgaard J, Nilsson A, Vickman K, Isaksson OGP 1989 Growth hormone regulates the level of insulin-like growth factor-I mRNA in rats skeletal muscle. J Endocrinol 120:107-112
13. Delafontaine P 1995 Insulin-like growth factor I and its binding proteins in the cardiovascular system. Cardiovasc Res 30:825-834
14. Han VK, D'Ercole AJ, Lund PK 1987 Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 236:193-197
15. Cittadini A, Stromer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS 1996 Differential cardiac effects of growth hormone and insulin-like growth factor-I in the rat. A combined in vivo and in vitro evaluation. Circulation 93:800-809
16. Lu C, Schwartzbauer G, Sperling MA, Devaskar SU, Thamotharan S, Robbins PD, McTiernan CF, Liu JL, Jiang J, Frank SJ, Menon RK 2001 Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem 276:22892-22900
17. Vetter U, Kupferschmid C, Lang D, Pents S 1988 Insulin-like growth factors and insulin increase the contractility of neonatal rat cardiocytes in vitro. Basic Res Cardiol 83:647-654
18. Vitale G, Pivonello R, Galderisi M, D'Errico A, Spinelli L, Lupoli G, Lombardi G, Colao A 2001 Cardiovascular complications in acromegaly: methods of assessment. Pituitary 4:251-257
19. Hejtmancik MR, Bradfield JY, Herrmann GR 1951 Acromegaly and the heart: a clinical and pathologic study. Ann Intern Med 34:1445-1456
20. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A 2000 Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193-199
21. Colao A, Marzullo P, Di Somma C, Lombardi G 2001 Growth hormone and the heart. Clin Endocrinol (Oxf) 54:137-154
22. Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G 2000 Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 85:3132-3140
23. Baldelli R, Ferretti E, Jaffrain-Rea ML, Iacobellis G, Minniti G, Caracciolo B, Moroni C, Cassone R, Gulino A, Tamburrano G 1999 Cardiac effects of lanreotide, a slow release somatostatin analog in acromegalic patients. J Clin Endocrinol Metab 84:527-532
24. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G 1999 Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 84:17-23
25. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S; The Pituitary Society and the European Neuroendocrine Association 2003 Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242-1247
26. Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Pivonello R, Salvatore M, Lombardi G 2001 Is the acromegalic cardiomyopathy reversible? Effect of 5 year normalization of growth hormone and insulin-like growth factor-I levels on cardiac performance. J Clin Endocrinol Metab 86:1551-1557
27. Colao A, Marzullo P, Cuocolo A, Spinelli L, Landi ML, Bonaduce D, Salvatore M, Lombardi G 2003 Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue Octreotide. Clin Endocrinol 58:169-176
28. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML 2005 Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 90:5684-5691